Ipsen's Groundbreaking

ASCO 2023: Ipsen's Groundbreaking Study Reveals Superior Overall Survival (OS) with NALIRIFOX in First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma.

ASCO 2023: How NALIRIFOX Can Extend the Lives of Patients with Metastatic Pancreatic Cancer

SG Tylor

ABSTRACT NUMBER – 4006 The combination of liposomal irinotecan with 5-fluorouracil/leucovorin (5-FU/LV) has already received approval for treating metastatic pancreatic ...